Skip to main navigation
Skip to search
Skip to main content
Northwestern Scholars Home
Help & FAQ
Home
Experts
Organizations
Research Output
Grants
Core Facilities
Research Data
Search by expertise, name or affiliation
Isradipine versus placebo in early Parkinson disease a randomized trial
Tanya Simuni
*
*
Corresponding author for this work
Neurology
Research output
:
Contribution to journal
›
Article
›
peer-review
74
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Isradipine versus placebo in early Parkinson disease a randomized trial'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Adjusted Least Squares
12%
Adverse Effects
12%
Antiparkinsonian Drugs
50%
Calcium Channel
12%
Clinical Progression
25%
Dihydropyridine Calcium Channel Blockers
25%
Disability
12%
Disease Duration
25%
Dizziness
12%
Double-blind Placebo-controlled Trial
12%
Early Parkinson's Disease
100%
Edema
12%
I to
25%
Immediate Release
25%
Isradipine
100%
Least Mean Square
12%
Long-term Treatment
12%
Medication Use
12%
Motor Complications
12%
Neuroprotective Effect
12%
Non-motor
12%
North America
12%
On-state
25%
Parkinson
12%
Parkinson's Disease
25%
Patient-completed
12%
Placebo
100%
Quality of Life Assessment
12%
Randomized Trial
100%
Risk Reduction
12%
Statistical Adjustment
12%
Time to Initiation
12%
Time to Onset
12%
Treatment Effect
12%
Twice Daily
12%
Unified Parkinson's Disease Rating Scale (UPDRS)
37%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
12%
Antiparkinson Agent
50%
Calcium Channel
12%
Calcium Channel Blocker
25%
Dihydropyridine
25%
Disease Duration
25%
Dizziness
12%
Dopamine Receptor Stimulating Agent
12%
Edema
12%
Isradipine
100%
Neuroprotective Agent
12%
Parkinson's Disease
100%
Placebo
100%